ArticleSaudi medical journal2025
The relationship of ST6GAL1 with clinicopathological and prognostic factors in breast carcinomas.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association of β-galactoside α2-6 sialyltransferase 1 (ST6GAL1) expression with hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), and other clinicopathological parameters, including histological grade, stage, lymphovascular invasion, perineural invasion, and survival in breast carcinomas (BCs).
methodsThis study included 85 patients who had undergone surgery for breast cancer (BC). The associations of HR, HER2 status, and histopathologic tumor characteristics with immunohistochemical expression of ST6GAL1 were analyzed.
resultsThe majority (48 [56.5%]) of patients were in the T2 stage, and no association was seen between staging and ST6GAL1 (
conclusionThis research is one of the first studies to use ST6GAL1 in preoperative biopsies of patients not scheduled for neoadjuvant treatment. This study revealed highly significant associations of ST6GAL1 expression with HR, HER2, and molecular subtyping. Future studies are recommended to clarify the possible role of ST6GAL1 in resistance to HR and HER2-targeted and other chemotherapeutic agents in BCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.